N-of-1 Trials

What are N-of-1 Trials? 

N-of-1 trials are a way to test different treatment options in patients. These personalized trials can be used to test how you feel when you continue versus when you stop a medication. At the end of N-of-1 trials, you and your doctor can review the data and decide together whether to continue or stop the medication. 

Click here to see a short video about N-of-1 trials, which Dr. Goyal and his team are developing for the purposes of optimizing medication regimens in older adults with cardiovascular disease.   

Trials Open to Enrollment

N-of-1 for Beta-Blockers in Cardiac Amyloidosis

N-of-1 Trials to Promote Deprescribing in Older Adults With Transthyretin Cardiac Amyloidosis

The goal of this study is to generate preliminary data on whether patients with cardiac amyloidosis feel better when their beta-blocker is stopped. To achieve this objective, 20 N-of-1 trials (on vs. off) will be conducted, and the study team will subsequently interview participants to better understand their outcomes. We will also engage stakeholders to understand the acceptability and feasibility of deprescribing N-of-1 trials.

Research Coordinator: Maryam Hyder - mah4022@med.cornell.edu

Status: Enrolling 


A PREliminary Study for the Intervention of an N-of-1 protocol FOR MEDication optimization (PRE-INFORMED)

PRE-INFORMED aims to determine whether N-of-1 trials, a pragmatic, patient-centered approach to medication optimization that can overcome key barriers of deprescribing, can lead to increased patient confidence regarding the decision to continue or discontinue beta-blockers in older adults with Heart Failure with Preserved Ejection Fraction (HFpEF).

Research Coordinator: Princess Osma - pro4001@med.cornell.edu

Status: Enrolling 

Trials Closed to Enrollment

Pilot Deprescribing N-of-1 Trials for Beta-blockers in HFpEF

N-of-1 Trials for Deprescribing Beta-blockers in HFpEF

This study tested the feasibility of N-of-1 trials for deprescribing beta-blockers in patients with Heart Failure with Preserved Ejection Fraction. To achieve this objective, we conducted 4-period N-of-1 trials (on vs. off) and subsequently interviewed participants to better understand feasibility and pragmatism.